Romi Bloom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Romi Bloom has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kyle T. Amber
Department of Dermatology Rush University Medical Center Chicago Illinois USA
7 shared publications - Antonella Tosti
University of Miami Miller School of Medicine
2 shared publications Keyvan Nouri
Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, 10660 SW 75th Ave., Miami, FL, 33156, USA
2 shared publicationsM. Hertl
Department of Dermatology and Allergology, Phillipps University, Marburg, Germany
2 shared publicationsBrian W. Morrison
Department of Dermatology and Cutaneous Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, Florida
1 shared publicationJohn Lee
MacNeal Hospital, Berwyn, IL, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2016
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 82 (2) , 182-3
The controversy of hepatitis C and rituximab: A multidisciplinary dilemma with implications for patients with pemphigus
- 1 January 2016
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 82 (2) , 182-3
Open AccessThe controversy of hepatitis C and rituximab: A multidisciplinary dilemma with implications for patients with pemphigus
- 7 October 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (1) , 72-77
A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti‐laminin‐332 IgG with oropharyngeal involvement and the usefulness of ELISA
Background: Mucous membrane pemphigoid (MMP) is characterized by subepithelial blistering due to IgG autoantibodies targeting various components of the dermal–epidermal basement membrane zone. Immunodiagnostics play an important role in making a precise diagnosis. Measures of test sensitivity and specificity, however, typically come from studies in diseases such as bullous pemphigoid, where the exact antigenic site may not be the same. Additionally, the association of clinical phenotype and autoantibody profiles has been an area of debate.Objective: We evaluated the sensitivity and specificity of ELISA in MMP for the known target antigens BP180 and laminin‐332, as well as characterized the frequency of IgG antibodies against each laminin‐332 subdomain. Lastly, we analysed whether IgG auto‐antibody profiles were associated with clinical phenotype.Methods: We performed a systematic review of Medline/PubMed to compile MMP patient demographics, clinical manifestations and immunodiagnostic results. ELISA sensitivities and specificities for autoantigens were calculated in patients with positive immunoblot or immunoprecipitationstudies. IgG reactivity for each laminin‐332 subunit was recorded. Associations between positive immunological tests and clinical presentation were evaluated using chi‐squared test tests or Fisher's exact test when appropriate.Results: For patients with a positive immunoblot or immunoprecipitation to NC16a, ELISA using both the NC16a and C‐terminal portion of BP180 demonstrated a sensitivity and specificity of 73% and 93%. However, for individuals with IgG against the C‐terminal domain of BP180, the sensitivity and specificity was 43% and 56%, respectively. LN‐332 ELISA demonstrated 75% sensitivity, but only for patients with IgG reactivity against the α3 subunit. In patients with laminin‐332 MMP, 86.4% demonstrated IgG against the α3 subunit. IgG autoantibodies against laminin‐332 are significantly associated with pharyngo‐laryngeal (P < 0.0001) and oro‐pharyngo‐laryngeal (P = 0.006) involvement.Conclusions: Immunodiagnostics play a major role in diagnosing MMP, though limited sensitivity may necessitate several forms of testing for confirmation.
- 7 October 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (1) , 72-77
A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti‐laminin‐332 IgG with oropharyngeal involvement and the usefulness of ELISA
Background: Mucous membrane pemphigoid (MMP) is characterized by subepithelial blistering due to IgG autoantibodies targeting various components of the dermal–epidermal basement membrane zone. Immunodiagnostics play an important role in making a precise diagnosis. Measures of test sensitivity and specificity, however, typically come from studies in diseases such as bullous pemphigoid, where the exact antigenic site may not be the same. Additionally, the association of clinical phenotype and autoantibody profiles has been an area of debate.Objective: We evaluated the sensitivity and specificity of ELISA in MMP for the known target antigens BP180 and laminin‐332, as well as characterized the frequency of IgG antibodies against each laminin‐332 subdomain. Lastly, we analysed whether IgG auto‐antibody profiles were associated with clinical phenotype.Methods: We performed a systematic review of Medline/PubMed to compile MMP patient demographics, clinical manifestations and immunodiagnostic results. ELISA sensitivities and specificities for autoantigens were calculated in patients with positive immunoblot or immunoprecipitationstudies. IgG reactivity for each laminin‐332 subunit was recorded. Associations between positive immunological tests and clinical presentation were evaluated using chi‐squared test tests or Fisher's exact test when appropriate.Results: For patients with a positive immunoblot or immunoprecipitation to NC16a, ELISA using both the NC16a and C‐terminal portion of BP180 demonstrated a sensitivity and specificity of 73% and 93%. However, for individuals with IgG against the C‐terminal domain of BP180, the sensitivity and specificity was 43% and 56%, respectively. LN‐332 ELISA demonstrated 75% sensitivity, but only for patients with IgG reactivity against the α3 subunit. In patients with laminin‐332 MMP, 86.4% demonstrated IgG against the α3 subunit. IgG autoantibodies against laminin‐332 are significantly associated with pharyngo‐laryngeal (P < 0.0001) and oro‐pharyngo‐laryngeal (P = 0.006) involvement.Conclusions: Immunodiagnostics play a major role in diagnosing MMP, though limited sensitivity may necessitate several forms of testing for confirmation.
- 26 August 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (11) , 2104-2111
TNF‐α: a treatment target or cause of sarcoidosis?
Sarcoidosis is a systemic granulomatous disease that affects numerous organs, commonly manifesting at the lungs and skin. While corticosteroids remain the first line of treatment, tumour necrosis factor alpha (TNF‐α) inhibitors have been investigated as one potential steroid sparing treatment for sarcoidosis. TNF‐α is one of many components involved in the formation of granulomas in sarcoidosis. While there have been larger scale studies of biologic TNF‐α inhibition in systemic sarcoidosis, studies in cutaneous disease are limited. Paradoxically, in some patients treated with biologic TNF‐α inhibitors for other diseases, treatment can induce the development of sarcoidosis. In the light of this complexity, we discuss the role of TNF‐α in granuloma formation, the therapeutic role of TNF‐α inhibition and immunologic abnormalities following treatment with these TNF‐α inhibitors including drug‐specific alterations involving interferon‐γ, lymphotoxin‐α, TNF receptor 2 (TNFR2) and T‐regulatory cells.
- 26 August 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (11) , 2104-2111
TNF‐α: a treatment target or cause of sarcoidosis?
Sarcoidosis is a systemic granulomatous disease that affects numerous organs, commonly manifesting at the lungs and skin. While corticosteroids remain the first line of treatment, tumour necrosis factor alpha (TNF‐α) inhibitors have been investigated as one potential steroid sparing treatment for sarcoidosis. TNF‐α is one of many components involved in the formation of granulomas in sarcoidosis. While there have been larger scale studies of biologic TNF‐α inhibition in systemic sarcoidosis, studies in cutaneous disease are limited. Paradoxically, in some patients treated with biologic TNF‐α inhibitors for other diseases, treatment can induce the development of sarcoidosis. In the light of this complexity, we discuss the role of TNF‐α in granuloma formation, the therapeutic role of TNF‐α inhibition and immunologic abnormalities following treatment with these TNF‐α inhibitors including drug‐specific alterations involving interferon‐γ, lymphotoxin‐α, TNF receptor 2 (TNFR2) and T‐regulatory cells.
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 337-338
Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 337-338
Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States
- 23 April 2015
- Published by Springer Nature in Lung
- Vol. 193 (4) , 593-596
A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman’s Disease is the Predominant Malignancy
Paraneoplastic autoimmune multiorgan syndrome (PAMS) is a rare disorder that manifests with severe mucocutaneous blistering and erosions accompanied by underlying malignancy. Constrictive bronchiolitis (CB) can occur in a subset of patients. We sought to characterize the particular group of PAMS patients with CB by comparing the underlying tumor in these patients versus all reported PAMS patients.
- 23 April 2015
- Published by Springer Nature in Lung
- Vol. 193 (4) , 593-596
A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman’s Disease is the Predominant Malignancy
Paraneoplastic autoimmune multiorgan syndrome (PAMS) is a rare disorder that manifests with severe mucocutaneous blistering and erosions accompanied by underlying malignancy. Constrictive bronchiolitis (CB) can occur in a subset of patients. We sought to characterize the particular group of PAMS patients with CB by comparing the underlying tumor in these patients versus all reported PAMS patients.
- 19 March 2015
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 57 (3) , e114-6
An increased risk of non‐Hodgkin lymphoma and chronic lymphocytic leukemia in US patients with Merkel cell carcinoma versus Australian patients: A clinical clue to a different mechanism of pathogenesis?
The US and Queensland populations both demonstrate an increased risk of secondary malignancies following the diagnosis of Merkel cell carcinoma (MCC). A recent Queensland study failed to demonstrate a significantly increased risk of developing non‐Hodgkin lymphoma (NHL) or chronic lymphocytic leukaemia (CLL) in these patients. In contrast, using the US Surveillance, Epidemiology, and End Results database, we demonstrate there is an increased risk in CLL and NHL following the diagnosis of MCC in the USA. We hypothesise that this difference may be a result of a differing pathogenesis.
- 19 March 2015
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 57 (3) , e114-6
An increased risk of non‐Hodgkin lymphoma and chronic lymphocytic leukemia in US patients with Merkel cell carcinoma versus Australian patients: A clinical clue to a different mechanism of pathogenesis?
The US and Queensland populations both demonstrate an increased risk of secondary malignancies following the diagnosis of Merkel cell carcinoma (MCC). A recent Queensland study failed to demonstrate a significantly increased risk of developing non‐Hodgkin lymphoma (NHL) or chronic lymphocytic leukaemia (CLL) in these patients. In contrast, using the US Surveillance, Epidemiology, and End Results database, we demonstrate there is an increased risk in CLL and NHL following the diagnosis of MCC in the USA. We hypothesise that this difference may be a result of a differing pathogenesis.
- 1 November 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (5) , e201
The figure 8: A new hair biopsy technique
- 1 November 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (5) , e201
The figure 8: A new hair biopsy technique
- Open Access
- 15 May 2014
- Published by Wiley in Journal of Skin Cancer
- Vol. 2014, 1-7
Assessing the Current Market of Sunscreen: A Cross-Sectional Study of Sunscreen Availability in Three Metropolitan Counties in the United States
Sunscreen use is recommended for the prevention of sunburn and skin cancer. Little is known regarding sunscreen availability in high versus low income communities. We analyzed sunscreen availability in three large metropolitan counties to determine the relationship between availability and community demographics. We included sun care products in all pharmacies and supermarkets open as of July 2013 in representative high and low income zip codes in Cook County, Illinois, Miami-Dade County, Florida, and San Diego County, California. We recorded the percentage of tanning oil, sunscreens with a sun protection factor (SPF) < 15, SPF > 15, physical sunscreens, spray sunscreens, mean price per ounce (PPO), and mean SPF. Of the total products assessed, 11.0% were tanning oils, with physical sunscreens accounting for only 3.4% of the available sunscreens and 46.2% of sunscreens being spray-on. A comparison between higher and lower income zip codes demonstrated a significantly increased percentage of sunscreens with SPF < 15 in high income zip codes. Lower income zip codes had higher percentages of sunscreens with SPF > 15 and higher PPO, even when taking into account SPF. Further studies of sunscreen usage patterns in different populations must take into account sunscreen availability and price, as these significantly differ based on the community demographic.
- 15 May 2014
- Published by Wiley in Journal of Skin Cancer
- Vol. 2014, 1-7
Open AccessAssessing the Current Market of Sunscreen: A Cross-Sectional Study of Sunscreen Availability in Three Metropolitan Counties in the United States
Sunscreen use is recommended for the prevention of sunburn and skin cancer. Little is known regarding sunscreen availability in high versus low income communities. We analyzed sunscreen availability in three large metropolitan counties to determine the relationship between availability and community demographics. We included sun care products in all pharmacies and supermarkets open as of July 2013 in representative high and low income zip codes in Cook County, Illinois, Miami-Dade County, Florida, and San Diego County, California. We recorded the percentage of tanning oil, sunscreens with a sun protection factor (SPF) < 15, SPF > 15, physical sunscreens, spray sunscreens, mean price per ounce (PPO), and mean SPF. Of the total products assessed, 11.0% were tanning oils, with physical sunscreens accounting for only 3.4% of the available sunscreens and 46.2% of sunscreens being spray-on. A comparison between higher and lower income zip codes demonstrated a significantly increased percentage of sunscreens with SPF < 15 in high income zip codes. Lower income zip codes had higher percentages of sunscreens with SPF > 15 and higher PPO, even when taking into account SPF. Further studies of sunscreen usage patterns in different populations must take into account sunscreen availability and price, as these significantly differ based on the community demographic.